Poster: AML-190 Targeted Therapy for R/R FLT3-Positive Acute Myeloid Leukemia is as Effective as Salvage Intensive Chemotherapy but Less Toxic and With Better Long-Term Results

Irina Budaeva,Aleksina Shatilova, Dmitrij Motorin,Vladimir Ivanov,Konstantin Bogdanov,Yuliya Mirolyubova,Tatiana Nikulina,Ksenia Levchuk,Alina Ershova,Yuliya Alekseeva,Larisa Girshova

Clinical Lymphoma Myeloma and Leukemia（2022）

引用 0|浏览8

暂无评分

摘要

Gilteritinib therapy is comparable in efficacy to salvage IC in patients with FLT3-mutated R/R AML but has been shown to be safer and have better survival rates. Gilteritinib is an optimal bridge therapy to allogeneic BMT.

查看译文

关键词

AML,gilteritinib,venetoclax,azacitidine,relapse,refractory

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要